Another indication of the possible usage of Grx as a biomarker in specific tumours come from studies reporting Increased expression of Grx3 specifically in colon [220] and in bladder tumours [221] while Grx1 has been reported as a possible malignant marker in pancreatic duct carcinomas [222] and in the study by Zhao and collaborators, who sought non-invasive urinary markers for HCC, Grx1 expression decreased [219]. Here, GLRX is linked to hepatocellular carcinoma.